Michele Gerber obtained her M.D. and MPH at the University of Michigan. She is a rheumatologist with over 15 years of clinical experience and research at the University of Michigan and over 12 years of experience as a clinical immunologist in the pharmaceutical industry. She has been a leader in global clinical phase 1-4 trials, studying many ground-breaking therapeutics.
Her most recent positions have included Global Clinical Lead at Takeda for a stem cell therapy for Crohn’s perianal fistula which was approved in Europe and being studied in the US and Japan. She was also the clinical lead from Takeda for TIMP-GLIA, a nanoparticle for celiac disease and the first therapeutic shown to induce tolerance in any autoimmune disease. In addition, she has contributed to multiple INDs and NDAs.